Cardiovascular benefits linked with the SGLT2 inhibitor drug canagliflozin seem like dose-dependent, with benefits in some key scientific endpoints — including mortality — seen handiest within the elevated of the 2 key doses of 300 mg and 100 mg of the drug, new compare exhibits…
Learn Extra
2025-06-09
